Abstract
Background Use of PICCs has been rising since 2001. They are used when long-term intravenous access is needed and for blood draws in patients with difficult venous access.
Objective To determine which risk factors contribute to inappropriate PICC line insertion defined as removal of a PICC within five days of insertion for reasons other than a PICC complication.
Design Retrospective, observational study.
Setting Tertiary-care, Level 1 trauma center.
Patients Adult patients with a PICC removed 1/1/2017 to 5/4/2020.
Measurements Frequency of PICC removal within five days of insertion and associated risk factors for early removal.
Results Between 1/1/17 and 5/4/2020, 995 of 5348 PICCs inserted by the IV nursing team were removed within five days (19%). In 2017, 5 of 429 PICCs developed a central line-associated infection (1.2%) and 29 of 429 PICCs developed symptomatic venous thromboembolism (6.7%). Patients with PICCs whose primary service was a medical subspecialty were independently at higher risk of early removal (OR 1.44, 95% CI 1.14, 1.83); weekday insertion was independently associated with a lower likelihood of early removal compared to weekend insertion (OR 0.60; 95% CI 0.49, 0.75).
Limitation PICC removal after discharge was not assessed and paper records were likely incomplete and biased.
Conclusion Nearly one in five PICCs were removed within five days. Patients whose primary team was a medical subspecialty were at independently higher risk of early removal.
Competing Interest Statement
I have read the journal's policy and the authors of this manuscript have the following competing interests: Dr. Mermel serves as a consultant for Light Line Medical Citius Pharmaceutical, and Destiny Pharma. The other authors have indicated they have no potential conflicts of interest to disclose.
Funding Statement
The authors received no specific funding for this work
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Not Applicable
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Lifespan Institutional Review Board approved this project, reference number 214718 45CFR 46.110(5). Consent was not obtained because the data were analyzed anonymously.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Not Applicable
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Not Applicable
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Not Applicable
Footnotes
Funding Source: No external funding for this manuscript
Potential Conflicts of Interest: Dr. Mermel serves as a consultant for Light Line Medical Citius Pharmaceutical, and Destiny Pharma. The other authors have indicated they have no potential conflicts of interest to disclose.
Data Availability
All relevant data are within the manuscript and its Supporting Information files.
